Trending Topics

 

Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at williamr@mskcc.org.
Monday, April 10, 2017
 
Memorial Sloan Kettering experts are available to comment on the promising new research presented at the American Association for Cancer Research (AACR) Annual Meeting, including precision medicine, immunotherapy, screening, prevention, health equity, data sharing, the Cancer Moonshot Initiative, and more. For more information and to set up interviews or access photos and video, email Nicole H. McNamara at mcnamarn@mskcc.org.
Friday, March 31, 2017
 
Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact mcnamarn@mskcc.org.
Thursday, March 23, 2017
 
See all trending topics
 

Press Releases

 
Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine. Dr. Diaz formally assumes the role as David Spriggs, MD, steps down after nearly 13 years.
Monday, April 17, 2017
 
Jae Park, MD, a hematologic oncologist and assistant attending physician at MSK, will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American Association for Cancer Research (AACR) Annual Meeting. This research has been selected to be featured in the meeting’s press program.
Monday, April 3, 2017
 
Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the oldest and largest professional organization dedicated to advancing cancer research, and the press program highlights cancer research that a panel of AACR experts considers the most significant of the year and deserving of media attention.
Sunday, April 2, 2017
 
See all press releases
 

On Our Blog

 
IN THE CLINIC
A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).
Friday, April 21, 2017
 
IN THE CLINIC
MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.
Tuesday, April 11, 2017
 
FINDING
Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.
Monday, April 10, 2017
 
See all blog posts
 

Media Coverage

 
Radiation oncologist Michael Zelefsky discusses radiation therapy in an interview with The New York Times
Tuesday, March 21, 2017
 
Oncology fellow Ryan Merkow discusses care guidelines for cancer survivors in Reuters Heath
Monday, March 20, 2017
 
Medical oncologist Michael Postow discusses immunotherapy in an interview with Wired UK
Monday, March 20, 2017
 
See all media coverage
 

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at marketing@mskcc.org.

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
 
Emily O'Donnell
Senior Communications Associate, Department of Surgery
 
Courtney Nowak
Senior Media Relations Associate
 
Caitlin Hool
Senior Media Associate
 
Nicole H. McNamara
Senior Media Relations Associate
 
Rebecca Williams
Media Associate
 
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
 
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.

News@MSKCC

Get the latest information from our media staff on advances in research at MSK.

Newsletter Sign Up Unsubscribe